Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM and to assess the improvement in stool consistency and quality of life in these patients and to assess the safety of cholestagel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

NCT05542355

Crohn Disease

TERMINATED PHASE1

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

NCT00114465

Crohn's Disease

COMPLETED PHASE4

Tofacitinib Registry of Patients With Ulcerative Colitis in Germany

NCT04032756

Colitis, Ulcerative Biologics Tofacitiniib +4 more

TERMINATED

Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.

NCT00259571

Ulcerative Colitis

WITHDRAWN PHASE2/PHASE3

The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer

NCT02769494

Crohn's Disease Oral Ulcer

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohns Disease Bile Acid Malabsorption

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablet: 3 times daily 2 tablets

Cholestagel

Group Type ACTIVE_COMPARATOR

Colesevelam

Intervention Type DRUG

Colesevelam 625 mg tablet; 3 times daily 2 tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colesevelam

Colesevelam 625 mg tablet; 3 times daily 2 tablets

Intervention Type DRUG

Placebo

Placebo tablet: 3 times daily 2 tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent after adequate explanation of the patient information.
* Male and female patients with CD and 18 to 65 years of age in clinical remission with a Crohns Disease Activity Index (CDAI) score of 150 or less, with symptoms of functional BAM or symptoms of BAM after small bowel resection with a frequency of at least 3 to maximal 15 liquid or soft stools per day.
* Stable medical treatment of CD for a minimal period of 3 months preceding the screening visit, consisting of

* either continuous oral treatment of aminosalicylate, prednisolone (a maximum 10 mg/day), azathioprine, 6-mercaptopurine, or methotrexate
* or supporting periodic treatment\* with TNF-alpha AK (Infliximab, Adalimumab, Certolizumab) (for patients on TNF-alpha, dosing with TNF-alpha should coincide with baseline visit)
* Blood serum CRP value of less or equal then 1 mg/dl (10 mg/l).
* BAM assessed with a blood test on a 7α-hydroxy-4-cholesten-3-on excretion of equal or more than 50 ng/ml

Exclusion Criteria

* Allergy or hypersensitivity to any of the components of cholestagel or placebo as identified from the medical history
* Participation at another clinical trial within a period of 4 weeks before the screening visit
* Presence of any addiction, alcohol abuse or specific disease that would not allow the patient to understand the essence and requirements and potential consequences of the participation to the clinical trial
* Signs suggestive of the patient being unable to follow the visit schedule as required (for example for professional obligations)
* Treatment with cyclosporine, or tacrolimus, 3 month or less before screening
* Oral Treatment with antibiotics 3 weeks or less before screening
* Topical treatment with steroid- or mesalazine-containing applications 3 weeks or less before screening
* Treatment with bile acid bile acid binding agent (e.g. Cholestayramine)6 weeks or less before screening
* Infectious diseases (HIV, hep B, hep C, tuberculosis, listeriosis, positive clostridium-difficile-toxin- proof in faeces)
* Current presence of intra-abdominal abscess or Fistula
* Cholestatic liver disease, bowel or biliary obstruction
* Dysphagia or swallowing disorders
* Known malignancy or history of malignancy
* Having undergone intestinal surgery within 6 months from screening
* Status after intestinal surgery with more then 100cm of resected bowel.
* Short bowel syndrome
* Planned -gastrostomy, ileostomy or colostomy.
* Pregnancy and lactation

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No